BCG vaccine’s off-target effects on allergic, inflammatory, and autoimmune diseases: Worth another shot? - 05/01/22
Doi : 10.1016/j.jaci.2021.09.034
Asimenia Angelidou, MD, PhD a, b, c, Laure F. Pittet, MD, PhD d, e, f, Denise Faustman, MD, PhD c, g, Nigel Curtis, MBBS, PhD d, h, Ofer Levy, MD, PhD b, c, i, ⁎ 
a Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, Mass
b Precision Vaccines Program, Division of Infectious Diseases, Boston Children’s Hospital, Boston, Mass
c Department of Pediatrics, Harvard Medical School, Boston, Mass
d Infectious Diseases Research Group, Murdoch Children’s Research Institute, Royal Children's Hospital Melbourne, Parkville, Australia
e Unit of Pediatric Infectious Diseases, Division of General Pediatrics, Department of Pediatrics, Gynecology and Obstetrics, Children's Hospital, University Hospitals of Geneva, Geneva, Switzerland
f Faculty of Medicine, University of Geneva, Geneva, Switzerland
g Department of Immunobiology, Massachusetts General Hospital, Boston, Mass
h Department of Paediatrics, The University of Melbourne, Melbourne, Australia
i Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Mass
∗Corresponding author: Ofer Levy MD, PhD, 4 Blackfan Circle, HIM Building, Rm 837A, Boston, MA 02115.4 Blackfan CircleHIM BuildingRm 837ABostonMA02115
Key words : Allergy, autoimmunity, Bacille Calmette-Guérin vaccine, BCG vaccine, inflammatory diseases
Le texte complet de cet article est disponible en PDF.
| Supported in part by the National Institutes of Health/National Institute of Allergy and Infectious Diseases Human Immunology Project Consortium (grant U19AI118608) and the Mueller Health Foundation (both to O.L.). The Precision Vaccines Program is supported in part by the Department of Pediatrics, Boston Children’s Hospital. |
|
| Disclosure of potential conflict of interest: O. Levy is a named inventor on vaccine adjuvant patent applications, as well as on an issued patent for an in vitro microphysiologic tissue construct platform for vaccine evaluation. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2021
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 149 - N° 1
P. 51-54 - janvier 2022 Retour au numéro
Article précédent
- Autoimmune consequences of biologics
- Rashmi Dhital, Arthur Kavanaugh
- Transcriptomic drug-response gene signatures are informative for the stratification of patients for clinical trials
- Paul S. Foster, Jessica L. Barnes, Hock L. Tay, Peter G. Gibson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?